Gavin Clark-Gartner
Stock Analyst
(n/a)
# 3,489
Out of 4,648 analysts
23
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JSPR Jasper Therapeutics | Maintains: Outperform | $65 | $22.03 | +195.05% | 2 | Aug 26, 2024 | |
| FHTX Foghorn Therapeutics | Initiates: Outperform | $20 | $8.24 | +142.72% | 1 | Aug 19, 2024 | |
| KRYS Krystal Biotech | Maintains: Outperform | $201 → $206 | $170.85 | +20.57% | 1 | Aug 12, 2024 | |
| CABA Cabaletta Bio | Maintains: Outperform | $25 → $15 | $4.00 | +275.00% | 1 | Aug 12, 2024 | |
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $185 → $179 | $123.07 | +45.45% | 8 | Aug 8, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $62 → $66 | $40.45 | +63.16% | 2 | Aug 8, 2024 | |
| ARGX argenx SE | Maintains: Outperform | $478 → $533 | $588.67 | -9.46% | 3 | Jul 12, 2024 | |
| ACRS Aclaris Therapeutics | Initiates: Outperform | $22 | $2.17 | +913.82% | 1 | Oct 3, 2023 | |
| CCCC C4 Therapeutics | Maintains: Outperform | $20 → $10 | $6.45 | +55.04% | 1 | May 30, 2023 | |
| ABBV AbbVie | Maintains: Outperform | $159 → $165 | $200.53 | -17.72% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $15.55 | +285.85% | 1 | Oct 5, 2022 |
Jasper Therapeutics
Aug 26, 2024
Maintains: Outperform
Price Target: $65
Current: $22.03
Upside: +195.05%
Foghorn Therapeutics
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $8.24
Upside: +142.72%
Krystal Biotech
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $170.85
Upside: +20.57%
Cabaletta Bio
Aug 12, 2024
Maintains: Outperform
Price Target: $25 → $15
Current: $4.00
Upside: +275.00%
Sarepta Therapeutics
Aug 8, 2024
Upgrades: Outperform
Price Target: $185 → $179
Current: $123.07
Upside: +45.45%
Mirum Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $62 → $66
Current: $40.45
Upside: +63.16%
argenx SE
Jul 12, 2024
Maintains: Outperform
Price Target: $478 → $533
Current: $588.67
Upside: -9.46%
Aclaris Therapeutics
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $2.17
Upside: +913.82%
C4 Therapeutics
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $6.45
Upside: +55.04%
AbbVie
Feb 9, 2023
Maintains: Outperform
Price Target: $159 → $165
Current: $200.53
Upside: -17.72%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $15.55
Upside: +285.85%